ARBs beat ACEIs for safety, study shows
Although both are considered first-line therapies, ARBs are associated with fewer adverse events, say US researchers
ARBs are preferable to ACEIs when initiating blood pressure-lowering therapy because of their superior safety, say researchers who led the largest comparative study to date.
Although both agents are considered first line, ACEIs are associated with a higher rate of adverse events, such as angioedema and pancreatitis, US researchers say.
